Deb K.D.,DiponEd BioIntelligence LLP |
Griffith M.,Linkoping University |
Griffith M.,Ottawa Health Research Institute |
De Muinck E.,Linkoping University |
Rafat M.,Linkoping University
Frontiers in Bioscience | Year: 2012
Human beings suffer from a myriad of disorders caused by biochemical or biophysical alteration of physiological systems leading to organ failure. For a number of these conditions, stem cells and their enormous reparative potential may be the last hope for restoring function to these failing organ or tissue systems. To harness the potential of stem cells for biotherapeutic applications, we need to work at the size scale of molecules and processes that govern stem cells fate. Nanotechnology provides us with such capacity. Therefore, effective amalgamation of nanotechnology and stem cells - medical nanoscience or nanomedicine - offers immense benefits to the human race. The aim of this paper is to discuss the role and importance of nanotechnology in stem cell research by focusing on several important areas such as stem cell visualization and imaging, genetic modifications and reprogramming by gene delivery systems, creating stem cell niche, and similar therapeutic applications.
Rajput B.S.,Criticare Multispeciality Hospital and Research Center |
Chakrabarti S.K.,DiponEd BioIntelligence LLP |
Dongare V.S.,DiponEd BioIntelligence LLP |
Ramirez C.M.,University of California at Los Angeles |
Deb K.D.,DiponEd BioIntelligence LLP
Journal of Stem Cells | Year: 2015
Objective: Duchenne muscular dystrophy (DMD) is a musculo-degenerative disease characterized by lack of dystrophin production with no definite cure available currently. Discarded umbilical cord is a potential source of mesenchymal stem cells which are non-immunogenic and can be used for transplantation in allogenic set ups. Given the regenerative and anti-inflammatory properties of mesenchymal stem cells (MSCs), here we investigated its role in the cellular therapy of DMD patients. Design: This is a single-blinded study conducted in various hospitals of India situated in Mumbai, Delhi, and Lucknow. Inclusion criteria for enrolling the patients in the study were boys aged between 5 to 18 years, absence of dystrophin in the immunohistochemistry of muscle biopsy and mutation in dystrophin gene in cytogenetic analysis. The exclusion criteria were presence of dystrophin in the muscle biopsy, patients on corticosteroids etc. UC-MSCs (2millions/kg body weight) were administered through IV and IM injection. Muscle power in muscles of proximal upper limb, distal upper limb, proximal lower limb, distal lower limb, hip flexors, hip extensors, hip abductors, and paraspinal muscles were measured in 11 DMD patients after UCMSCs transplantation and were followed for up to 3 years (average follow up 1.5 years). 5 DMD patients did not receive any UC-MSCs transplantation and served as the control group. Results: The treatment group (N=11 at baseline) had a pretransplantation strength of 3.45 ± 1.0357 and4.090 ± 0.8312 in muscles of proximal upper limb and distal upper limb respectively. After 1 year (N=9) these strengths remained stable with an average of 3.78 (1.03) and 4.22 (0.83). In contrast, the control group (N=5) has a pre-transplantation strength of 3.6 (0.54) and 4 (1) in the proximal and distal upper limb respectively. After 1 year, (N=5) 3/5 subjects had a slight but not statistically significant decrease in the proximal upper limb, mean 3.0 (1.0) and 5/5 had a 1unit decrease in strength, mean 3.0 (1.0). The treatment group had a pre-transplantation strength of 2.0909 ± 0.8312 and 3.1181 ± 0.8738 in muscles of distal and proximal lower limbs respectively. At 1 year (N=9), 4/9 subjects had a 1 unit increase in strength in the distal lower limb (mean 3.78 (0.97)) and 8/9 subjects had a 1unit increase in strength in the proximal lower limb, mean 3.11 (1.05). The control group has a mean of 3.41 (0.54) and 3.0 (1.0) at baseline in the distal and proximal lower limb respectively. By 1 year, 3/5 subjects had a 1 unit decrease (mean 2.8 (0.45)) and 5/5 had a 1unit decrease, mean 2.0 (1.0) in distal and proximal lower limb strength. Stability in muscle function was also achieved in muscles of hip flexors, hip extensors, hip abductors, and paraspinal muscles at one year as compared to untreated group. Conclusion: UC-MSCs administration not only resulted in the stabilization of muscle power but also did not show GVHD or any deleterious effects on the patients and thus may be considered as safe option for treatment of DMD as compared to control untreated group although further larger double-blinded studies are needed. © 2015 Nova Science Publishers, Inc.
Rajendran R.,DiponEd BioIntelligence LLP |
Gopal S.,DiponEd BioIntelligence LLP |
Masood H.,DiponEd BioIntelligence LLP |
Vivek P.,DiponEd BioIntelligence LLP |
Deb K.,DiponEd BioIntelligence LLP
Journal of Stem Cells | Year: 2013
Dental pulp are known to contains stem cells or dentinogenic progenitors that are responsible for dentin repair. Dental pulp Stem cells from Human Exfoliated Deciduous teeth (SHED) represent a population of postnatal stem cells capable of extensive proliferation and multipotential or multilineage differentiations. This potential for tissue regeneration has become the current basis for dental pulp stem cell banking. Here, we have attempted to develop a protocol for harvesting stem cells from patients with High Caries tooth, which are most often electively discarded. We have characterized the stem cells with mesenchymal stem cell markers and have compared their potential to grow in culture, doubling times, and differentiate into different lineages, with normal bone marrow mesenchymal stem cells (MSCs). We observed that the MSCs from dental pulp grew faster, with lower doubling time, and had equal efficiency in differentiating to various lineages, when subjected to standard directed differentiation protocols. This paper establishes that discarded High Carries Tooth can be a good source for regenerative medicine and also could be a potential source for MSCs and dental pulp MSC banking. © Nova Science Publishers, Inc.